机构地区:[1]广东省佛山市顺德区伍仲珮纪念医院老年科,佛山528333 [2]广东省佛山市顺德区伍仲珮纪念医院科教科,佛山528333 [3]广东省佛山市顺德区伍仲珮纪念医院心理科,佛山528333 [4]南方医科大学南方医院门诊部 [5]广东省食品药品监督管理局
出 处:《中华行为医学与脑科学杂志》2013年第2期120-123,共4页Chinese Journal of Behavioral Medicine and Brain Science
基 金:佛山市科技攻关计划项目(200808112)
摘 要:目的评价纳洛酮及纳洛酮联合氟哌啶醇治疗老年性谵妄的疗效及安全性,进一步探讨纳洛酮的治疗效果。方法采用前瞻性随机对照设计,分成3组:氟哌啶醇组、纳洛酮组以及两者联合组。分别在治疗前、治疗结束进行谵妄量表(DSS)测评。每天进行临床大体印象量表病情严重程度(CGI—SI)评分,评估起效时问及谵妄的改善情况。激越一镇静分级量表(ACES)在每次用药前后进行评分,评估对兴奋激越的效果。不良反应症状量表(TESS)测评药物毒副作用。结果氟哌啶醇组、纳洛酮组以及联合组用药时间[(4.0±2.9)d;(4.2±3.5)d;(3.2±3.2)d],3组多重比较差异无统计学意义(P〉0.05);起效时间[(2.4.4±1.6)d;(2.4±1.4)d;(1.3±0.9)d],联合组快于其他两组(均P〈0.05)。3组治疗结束DSS分别为[(18.8±11.5)分;(27.7±7.2)分;(29.5±5.6)分],纳洛酮组和联合组差异无统计学意义(P〉0.05),均较氟哌啶醇组恢复程度好(均P〈0.01);CGI—S1分别为[(3.3±1.5)分;(2.5±1.5)分;(1.8±0.9)分],联合组效果好于氟哌啶醇组(P〈0.01),和纳洛酮组差异无统计学意义(P〉0.05)。3组用药前ACES评分差异无统计学意义(P〉0.05),用药后分别为[(5.9±1.6)分;(6.2±1.8)分;(6.4±1.6)分],3组多重比较差异无统计学意义(P〉0.05);TESS测评氟哌啶醇组有4例锥体外系症状,联合组有2例,X^2检验差异无统计学意义(P〉0.05),纳洛酮组无副作用。结论在疗效方面,联合治疗及纳洛酮治疗均略优于氟哌啶醇治疗,联合治疗起效稍快于纳洛酮单独治疗;在副作用方面:氟哌啶醇治疗和联合治疗大体相当,纳洛酮无副作用。提示阿片系统也参与了谵妄的病理生理过程。Objective Compared with haloperidol treatment, naloxone and naloxone combined haloperidol treatments were assessed in their efficacy and safety for excited type delirium in elderly. Methods The elderly pa-tients with delirium were divided into halopelidol treatment (H), naloxone treatment (N) and combined treatment (C) in a prospective randomized controlled design. Delirium score scale (DSS) was used before and after treat- ments respectively. Clinical global impression scale-severity of illness (CGI-SI) score was evaluated daily to as- sess the onset time and improvement of delirium. Agitation-calmness evaluation scale (ACES) observed calmness effect in agitated patients before and after every medication intervention. Treatment emergent symptom scale (TESS) assessed side effects of all medications. Results The duration of three groups ( H (4.0 ± 2.9 ) d, N (4.2 ± 3.5 ) d, C ( 3.2 ± 3.2 ) d) had no significant difference (P 〉 0.05 ) by multiple comparison. Compared the onset time of three groups ( H (2.4 ± 1.6 ) d, N ( 2.4 ± 1.4 ) d, C ( 1.3 ± 0.9 ) d), the combined group was faster than the other two groups ( all P 〈 0.05 ), no significant difference between the two groups (P 〉 0.05 ). DSS scores had no significant differences (P〉 0.05 ) in three groups before treatment, so did CGI-SI scores. In the end, DSS scores were( H : 18.8 ± 11.5, N : 27.7 ± 7.2, C : 29.5 ± 5.6 ) respectively. Statistically naloxone group and combined group with no significant difference (P 〉 0.05 ), were better than the haloperidol group ( all P 〈 0.01 ) in recovery. At the same time CGI-SI scores were ( H : 3.3 ± 1.5, N :2.5 ± 1.5, C : 1.8 ± 0.9 ) respectively. Statistically com-bined group was better than the haloperidol group (P 〈 0.01 ), and no significant difference with naloxone group (P 〉 0.05 ). Three groups had no significant difference in ACES scores (P 〉 0.05 ) before and after medic
分 类 号:R74[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...